|Bid||18.18 x 1300|
|Ask||19.04 x 800|
|Day's Range||18.68 - 19.29|
|52 Week Range||17.99 - 22.75|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Traders were nervous the market volatility would adversely affect Tencent Music's public debut. Skeptics say that is shot across the bow to all those tech unicorns floating out there waiting to go public in 2019, and that we may see lower valuations than the companies want. Let's call this one "Disaster averted." Tencent Music TME .
(Bloomberg) -- On the Sunday before Moderna Inc. launched one of the biggest initial public offerings in biotechnology history, one of its earliest investors was giving a lecture about rocks.
Moderna (NASDAQ:MRNA) went public on Dec. 7, raising $604 million on a market cap of $7.5 billion. The IPO met the goal, but a bad day on Wall Street sent the shares plummeting. It’s because Moderna represents the next wave in drug discovery. Like Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna is less a bet on particular drugs than on a method for finding them.
Almost every issue the stock market is facing has two sides, Jim Cramer told his Mad Money viewers Monday, except for those that have three, four or even five. With so much uncertainty, having conviction makes you feel like an idiot, Cramer added, which is why the markets are so jittery. Fed Chair Jay Powell was adamant in October that he needed four interest rate hikes to cool the red-hot economy, but recently walked back those comments to only one hike in December.
There's more to Wall Street newcomer Moderna than the action in the biotechnology company's stock, says CNBC's Jim Cramer. The development-stage biotech has some "major" positive drivers that make its stock prime for speculation, the "Mad Money" host argues. Investors shouldn't draw conclusions about biotechnology company Moderna MRNA solely on the stock's worrisome action after its initial public offering, CNBC's Jim Cramer said Monday.
NEW YORK, NY / ACCESSWIRE / December 10, 2018 / Although Moderna sank in its first day of trading, the stock was still the biggest IPO in the biotech arena ever last week. Shares of Altria Group also hit red territory despite announcing it would take a whopping stake in Canadian marijuana company Cronos Group. Moderna, Inc. shares were down a little over 19% on Friday with nearly 13 million shares traded.
The company initially filed with the U.S. Securities and Exchange Commission back in early November to go public and it made its debut this morning, trading under the stock symbol MRNA. The Moderna Therapeutics IPO priced Thursday at $23 a share and began trading Friday. Outside of Moderna, there are 56 biotech IPOs that have raked in a total of $5.5 billion in 2018, making it the highest total since 2014.
Moderna, Inc. (MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, visited the Nasdaq MarketSite in Times Square today in celebration of its initial public offering (IPO) on the Nasdaq Stock Market. Moderna is a leader in the development of mRNA medicines, a new class of drugs that directs the body’s cells to produce proteins that have the potential to prevent, treat or cure disease. The company has a pipeline of 21 development candidates, including 10 programs currently in clinical trials.
Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions. The company had 332.9 million shares outstanding, including over-allotment. The IPO raised $604.3 million and eclipsed the $373 million raised by Allogene Therapeutics in October, which is the largest biotech since Axovant Sciences' $363 million IPO in 2015.
has raised $604.3 million for an initial public offering running up to its Nasdaq debut Friday -- but trading was down from the start, falling 5% to $21.84 by noon. The valuation is reportedly the largest for a biotechnology company since 2016. Moderna, which has no approved drugs yet, is working on personalized therapies for cancer and infectious and rare diseases.
Shares of Moderna Inc. opened at $22 Friday on the Nasdaq , or 4% below its initial public offering price, with the first trade crossing at 11:40 am Eastern for 2,249,704 shares. The IPO priced on Thursday at the middle of the company's expected range of $22 to $24 a share. Moderna sold 26.3 million shares to raise $604.3 million, the largest biotech offering to date. The company has gone public during a sluggish time for biotech stocks; the Nasdaq Biotechnology ETF was up 14% for the year through August, but is now down 0.4% in the year to date. The S&P 500 is up 0.4%.
Moderna Inc will sell around $604.3 million in shares in its initial public offering (IPO), the biotech company said on Thursday, braving stock market jitters to sell more stock than originally planned. In the biggest flotation of a biotechnology company since 2016, Moderna said it would sell roughly 26.3 million shares at $23 per share. Moderna had originally planned to sell 21.7 million shares for between $22 and $24 per share.
Moderna, Inc. , a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the pricing of its initial public offering of 26,275,993 shares of common stock at a public offering price of $23.00 per share, before underwriting discounts and commissions.
Moderna Inc is set to sell around $618 million in shares in its initial public offering (IPO) on Thursday, a person familiar with the matter said, braving stock market jitters to sell more stock than originally planned. In the biggest flotation of a biotechnology company since 2016, Moderna expected to sell roughly 26.86 million shares at $23 per share, the person said. The pricing was a good test of the IPO market as it came following another turbulent day in the U.S. stock market, amid investor concerns over the trade dispute between the United States and China.
Moderna Inc aimed to sell around $618 million in shares in its initial public offering on Thursday, a person familiar with the matter said, braving stock market jitters to sell more stock than originally ...
Ride-hailing company Lyft Inc beat bigger rival Uber Technologies Inc in filing for an initial public offering (IPO) on Thursday, defying the recent market jitters and taking the lead on a string of billion-dollar-plus tech companies expected to join Wall Street next year. Lyft's IPO will test investors' appetite for the most highly valued Silicon Valley companies and for the ride-hailing business, which has become a wildly popular service but remains unprofitable and has an uncertain future with the advance of self-driving cars. San Francisco-based Lyft, last valued at about $15 billion in a private fundraising round, did not specify the number of shares it was selling or the price range in a confidential filing with the U.S. Securities and Exchange Commission (SEC).
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Mogu Inc. (MOGU) will issue 4.75 million shares between $14 and $16 Wednesday on the New York Stock Exchange. The Chinese ...
The Moderna IPO is set to become the largest public debut of a venture capital-backed biotech company, after it announced terms that could raise $521 million.
Biopharma company Moderna Inc. set terms for its planned initial public offering on Wednesday, saying it plans to offer 21.7 million shares priced at $22 to $24 each. In a regulatory filing, the company said it is planning to list on Nasdaq, under the ticker symbol "MRNA". Morgan Stanley, Goldman Sachs and JPMorgan are lead managers on the deal with another eight banks acting as co-managers. Proceeds of the deal will be used to fund drug discovery and clinical development, to expand manufacturing facilities and on infrastructure to support the company's pipeline of drugs. "We are creating a new category of transformative medicines based on messenger RNA, or mRNA, to improve the lives of patients," the company said in its prospectus. RNA, or ribonucleic acid, transfers the instructions stored in DNA to make the proteins required by every living cell.
Marina Biotech, Inc. (MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis and pain, today announced that it has changed its name to Adhera Therapeutics, Inc. and that it will begin using the ticker ATRX, in each case effective October 9, 2018. This new name reflects the company’s mission to develop and commercialize unique pharmaceutical therapies and leverage technology to improve patient outcomes. "Many treatment regimens fail or have limited impact because of a lack of patient adherence which hinders the benefits of the intended treatment.